Is it Fair to Use Antibiotics After Laparoscopic Cholecystectomy for the Patients With Acutely Inflamed Gallbladder?

Overview

During the laparoscopic cholecystectomy for acute cholecystitis, most surgeons routinely use the postoperative antibiotics after surgery. However, there is no consensus regarding the actual need of postoperative antibiotics in these cases and the use of postoperative antibiotics remains controversial. Investigators will compare the surgical outcomes after laparoscopic cholecystectomy to the patients who has no evidence of systemic infection, according to the usage of postoperative antibiotics or not. The investigators expect that the routine use of postoperative antibiotics after laparoscopic cholecystectomy for acute cholecystitis gallbladder will have no effects on the postoperative morbidity.

Full Title of Study: “Is it Fair to Use Antibiotics After Laparoscopic Cholecystectomy for the Patients With Acutely Inflamed Gallbladder?; a Multicenter Randomized Controlled Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: June 2016

Detailed Description

Primary outcome of this study is the confirmation of safety in the cases of acute cholecystitis without postoperative antibiotics usage after laparoscopic cholecystectomy. For this purpose, the investigators compare the surgical infectious outcomes including the wound infection or abdominal infections according to the usage of postoperative antibiotics after laparoscopic cholecystectomy. Secondary outcome of this study is the confirmation of efficacy according to skip the use of postoperative antibiotics after laparoscopic cholecystectomy. The investigators estimate the efficacy using the comparing the outcomes such as duration of hospitalization according to the use of postoperative antibiotics or not.

Interventions

  • Drug: Cephalosporin
    • During the hospitalization, intake of pacetin, 2nd generation cephalosporin. 3 g per day divided into 3 times via intravenous route until the day of discharge. After discharge, oral intakes of 500mg each (1 pill of cefaclor, the 2nd generation cephalosporin every 12 hrs) for three days.
  • Drug: Placebo
    • During the period of hospitalization, Intake of placebo (normal saline). 30cc per day divided into 3 times via intravenous route until the day of discharge. After discharge, oral intakes of 1000mg each (2 pill of vitamin C every 12 hrs) for three days.

Arms, Groups and Cohorts

  • Experimental: Group A (cephalosporin)
    • During the period of hospitalization, intake of active drug (‘pacetin’, 2nd generation cephalosporin). 3 g per day divided into 3 times via intravenous route until the day of discharge. After discharge, oral intakes of 500mg each (1 pill of cefaclor, the 2nd generation cephalosporin every 12 hrs) for three days.
  • Placebo Comparator: Group B (placebo)
    • During the period of hospitalization, Intake of placebo (normal saline). 30cc per day divided into 3 times via intravenous route until the day of discharge. After discharge, oral intakes of 1000mg each (2 pill of vitamin C every 12 hrs) for three days.

Clinical Trial Outcome Measures

Primary Measures

  • Number of Participants With Infectious Postoperative Complications
    • Time Frame: 30 days
    • Incidence of infectious postoperative complications in patients who underwent a laparoscopic cholecystectomy due to grade I Tokyo guidelines for acute cholecystitis or grade II Tokyo guidelines for acute cholecystitis except the evidence of gallbladder perforation, with antibiotics or placebo

Secondary Measures

  • Duration of Hospitalization
    • Time Frame: participants will be followed for the duration of hospital stay, an expected average of 2 days
    • the duration between the operation day and the day of discharge

Participating in This Clinical Trial

Inclusion Criteria

  • grade I Tokyo guideline for acute cholecystitis – grade II Tokyo guideline for acute cholecystitis without the evidence of gallbladder perforation Exclusion Criteria:

  • chronic cholecystitis – gallbladder polyp or gallbladder cancer – the patient who underwent reduced port surgery – the patient who underwent common bile duct exploration during the operation – the patient who underwent concurrent operation – the patient who had past history of upper abdominal surgery – the patient who had a immunodeficiency state – the case which had a suspicion of delayed bile leakage – the case which had a incomplete cystic duct ligation – the patient who underwent open conversion surgery during the operation – the patient who had a high risk of bleeding

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Taeho Hong
  • Collaborator
    • Incheon St.Mary’s Hospital
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Taeho Hong, Professor – Seoul St. Mary’s Hospital
  • Overall Official(s)
    • Taeho Hong, Principal Investigator, Seoul St. Mary’s Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.